View All Blog Posts

Healthy Innovation Statement on COVID-19

Our thoughts are with those affected by the outbreak of COVID-19, the novel strain of the coronavirus, both here in Southeast Asia and around the globe. Addressing the global public health challenges presented by COVID-19 will require collaboration and partnership from stakeholders across the globe. Working together, governments, global health authorities and the private sector can develop solutions to diagnose, treat and prevent the further spread of COVID-19. Now, as always, policies that advance the benefits of healthy innovation are vital to solving public health crises.

For more information about how the industry is responding to the coronavirus crisis, please visit the International Federation of Pharmaceutical Manufacturers and Associations and the Pharmaceutical Research and Manufacturers of America.

Recent Blog Posts

Investments in Science and Innovation Thrived During COVID-19

A new report by the World Intellectual Property Organization (WIPO) found that investments into research and development (R&D) thrived at the height of the COVID-19 pandemic in 2020 and continued to boom in 2021. The report, Global Innovation Index 2022, indicates that innovation saw a spike, despite the pandemic-induced global recession and economic lockdowns in many countries.

Global Collaborations Are Helping Increase Access to COVID-19 Treatments Throughout Southeast Asia

Collaborations between governments, NGOs and private companies have helped research, develop, manufacture and deliver COVID-19 vaccines and treatments in record time. Biopharmaceutical companies were able to build on years of investments to develop safe and effective countermeasures. This demonstrates a model for health systems to effectively respond to public health threats in the future.